These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effects of aluminum hydroxide and famotidine on bioavailability of tosufloxacin in healthy volunteers. Minami R; Nakamura C; Inotsume N; Nakano M Antimicrob Agents Chemother; 1998 Feb; 42(2):453-5. PubMed ID: 9527806 [TBL] [Abstract][Full Text] [Related]
7. [Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones]. Iakovlev VP Antibiot Khimioter; 1998; 43(10):46-52. PubMed ID: 9825111 [No Abstract] [Full Text] [Related]
8. Fixed drug eruption caused by tosufloxacin tosilate. Nishijima S; Nakagawa M J Int Med Res; 1997; 25(6):359-63. PubMed ID: 9427169 [TBL] [Abstract][Full Text] [Related]
9. Stereoselective analysis of the disposition of tosufloxacin enantiomers in man. Minami R; Inotsume N; Nakamura C; Nakano M Eur J Clin Pharmacol; 1993; 45(5):489-91. PubMed ID: 8112381 [TBL] [Abstract][Full Text] [Related]
10. [Trovafloxacin]. Azanza JR; Ollero D; Sádaba B; García Quetglas E Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346 [No Abstract] [Full Text] [Related]
11. [A study on the distribution of T-3262 (tosufloxacin tosilate) in salivary glands of rats using microautoradiography]. Morihana T; Sakai H; Hayakawa H Jpn J Antibiot; 1989 Sep; 42(9):1868-72. PubMed ID: 2810749 [TBL] [Abstract][Full Text] [Related]
12. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Pletz MW; Petzold P; Allen A; Burkhardt O; Lode H Antimicrob Agents Chemother; 2003 Jul; 47(7):2158-60. PubMed ID: 12821462 [TBL] [Abstract][Full Text] [Related]
13. Diffusion of tosufloxacin into prostatic tissue. Uchibayashi T; Hisazumi H; Kanayama J; Kumano K Chemotherapy; 1992; 38(3):150-4. PubMed ID: 1380905 [TBL] [Abstract][Full Text] [Related]
14. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Allen A; Vousden M; Lewis A Chemotherapy; 1999; 45(6):496-503. PubMed ID: 10567781 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of fluoroquinolones in patients with renal insufficiency]. Iakovlev SV; Iakovlev VP; Izotova GN Antibiot Khimioter; 1995 Oct; 40(10):39-47. PubMed ID: 8660120 [No Abstract] [Full Text] [Related]
16. [Pharmacokinetics and safety of trovafloxacin]. Frías J; de los Angeles Gálvez M Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():36-42; discussion 47-52. PubMed ID: 10344097 [No Abstract] [Full Text] [Related]
17. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Allen A; Bygate E; Vousden M; Oliver S; Johnson M; Ward C; Cheon A; Choo YS; Kim I Antimicrob Agents Chemother; 2001 Feb; 45(2):540-5. PubMed ID: 11158752 [TBL] [Abstract][Full Text] [Related]
18. [Biliary excretion and clinical efficacy of T-3262 (tosufloxacin tosilate) administered in the treatment of cholecystitis]. Sugata F; Ohguri S; Takamura Y; Tominaga S; Iwamura K; Yamada T; Shibata H; Yamada N; Okabe K; Kato Y Jpn J Antibiot; 1989 Sep; 42(9):1873-81. PubMed ID: 2810750 [TBL] [Abstract][Full Text] [Related]
19. Trovafloxacin. Med Lett Drugs Ther; 1998 Mar; 40(1022):30-1. PubMed ID: 9529517 [No Abstract] [Full Text] [Related]